From Name

From Email

To Name

To Email

Message

Ribociclib shows overall survival benefit in patients with advanced breast cancer with visceral metastases

from Drop Topics

Ribociclib shows overall survival benefit in patients with advanced breast cancer with visceral metastases Drop Topics Results from an exploratory analysis of 2 phase 3 trials demonstrated significant overall survival (OS) benefit of Novartis’ ribociclib (Kisqali) in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases. READ MORE

more